4'-PrenyloxyresveratrolCAS# 69065-16-3 |
Quality Control & MSDS
Chemical structure
3D structure
Number of papers citing our products
| Cas No. | 69065-16-3 | SDF | Download SDF |
| PubChem ID | 5281724 | Appearance | Powder |
| Formula | C19H20O4 | M.Wt | 312.4 |
| Type of Compound | Phenols | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 5-[(E)-2-(2,4-dihydroxyphenyl)ethenyl]-2-(3-methylbut-2-enyl)benzene-1,3-diol | ||
| SMILES | CC(=CCC1=C(C=C(C=C1O)C=CC2=C(C=C(C=C2)O)O)O)C | ||
| Standard InChIKey | FEHGVKWVMWWVQZ-SNAWJCMRSA-N | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Targets | PAFR |
4'-Prenyloxyresveratrol Dilution Calculator
4'-Prenyloxyresveratrol Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.201 mL | 16.0051 mL | 32.0102 mL | 64.0205 mL | 80.0256 mL |
| 5 mM | 0.6402 mL | 3.201 mL | 6.402 mL | 12.8041 mL | 16.0051 mL |
| 10 mM | 0.3201 mL | 1.6005 mL | 3.201 mL | 6.402 mL | 8.0026 mL |
| 50 mM | 0.064 mL | 0.3201 mL | 0.6402 mL | 1.2804 mL | 1.6005 mL |
| 100 mM | 0.032 mL | 0.1601 mL | 0.3201 mL | 0.6402 mL | 0.8003 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Peonidin-3-O-glucoside chloride
Catalog No.:BCN3028
CAS No.:6906-39-4
- Delphinidin-3-O-glucoside chloride
Catalog No.:BCN3020
CAS No.:6906-38-3
- Nedocromil
Catalog No.:BCC5283
CAS No.:69049-73-6
- Hydroxytyrosol acetate
Catalog No.:BCN2963
CAS No.:69039-02-7
- Grifolin
Catalog No.:BCN7553
CAS No.:6903-07-7
- Balapiravir
Catalog No.:BCC1396
CAS No.:690270-29-2
- ZM 306416
Catalog No.:BCC3964
CAS No.:690206-97-4
- Germacrone
Catalog No.:BCN4981
CAS No.:6902-91-6
- Genipin
Catalog No.:BCN5932
CAS No.:6902-77-8
- Tiotidine
Catalog No.:BCC5676
CAS No.:69014-14-8
- Toltrazuril sulfone
Catalog No.:BCC2008
CAS No.:69004-04-2
- Toltrazuril
Catalog No.:BCC4870
CAS No.:69004-03-1
- 2-Caren-10-ol
Catalog No.:BCN4253
CAS No.:6909-19-9
- Demanyl phosphate
Catalog No.:BCN1796
CAS No.:6909-62-2
- Acetoxyisovalerylalkannin
Catalog No.:BCN3007
CAS No.:69091-17-4
- 16-Hydroxy-8(17),13-labdadien-15,16-olid-19-oic acid
Catalog No.:BCN1378
CAS No.:691009-85-5
- Moracin C
Catalog No.:BCN4254
CAS No.:69120-06-5
- Moracin D
Catalog No.:BCN4255
CAS No.:69120-07-6
- Fiacitabine
Catalog No.:BCC1574
CAS No.:69123-90-6
- Aromadendrin 7-O-rhamnoside
Catalog No.:BCN8114
CAS No.:69135-41-7
- Malic acid
Catalog No.:BCN2699
CAS No.:6915-15-7
- Tigloylgomisin P
Catalog No.:BCN6926
CAS No.:69176-51-8
- Gomisin N
Catalog No.:BCN2271
CAS No.:69176-52-9
- (2S,3R,E)-2-Amino-4-heptadecene-1,3-diol
Catalog No.:BCN1765
CAS No.:6918-48-5
[Phenolic constituents from stem bark of Morus wittiorum and their anti-inflammation and cytotoxicity].[Pubmed:21246822]
Zhongguo Zhong Yao Za Zhi. 2010 Oct;35(20):2700-3.
To search for the chemical constituents possessing anti-inflammatory or cytotoxic activities from plants, Morus wittiorum was investigated for the first time. The stem bark of M. wittiorum was extracted with 95% EtOH. The EtOH extract was fractionationed on silica gel by eluting with petroleum ehter, CHCl3 and EtOAc successively. The further isolation and purification of the EtOAc fraction of 95% EtOH extract was performed by various column chromatography such as silica gel, Sephadex LH-20, RP-C18 column chromatography and so on. The structures of compounds were determined on the basis of spectral analysis such as NMR, MS etc. As a result, nine compounds were isolated including six flavonoids and three stilbenoids and elucidated as quercetin (1), 5, 7, 3', 4'-tetrahydroxy-3-methoxyflavone (2), norartocarpanone (3), dihydrokaempferol (4), euchrenone a7 (5), morachalcone A (6), resveratrol (7), oxyresveratrol (8), 4'-prenyloxyresveratrol (9). Compounds 1-9 were isolated from this plant for the first time, among which compounds 1-8 were evaluated for their anti-inflammatory and cytotoxic activities, respectively. Wherein compounds 6 and 8 showed inhibition to the release of beta-glucuronidase from rat polymorphonuclear leukocyte (PMNs) induced by platelet activating factor (PAF) at a concentration of 10(-5) mol x L(-1). The inhibitory ratios were 76.8%, 94.2% individually. Compounds 2 and 8 exhibited selective cytotoxicity agaist human ovarian cancer (A2780) and human gastric cancer (BGC-823) with IC50 values as 0.66, 1.31 micromol x L(-1) individually.
